EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia

Amgalan Byambasuren, Buyankhishig Gyarvuulkhasuren, Byambatsogt Erdenebat, Khurelbaatar Nyamdavaa, Oidov Baatarkhuu iD

Viruses · 2025

DOI: 10.3390/v17060743 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Amgalan Byambasuren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Benzimidazoles, Sofosbuvir. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Liver Disease Free Arkhangai project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Hepatitis C virus (HCV) infection poses a significant health burden, particularly in Mongolia, where the HCV prevalence is notably high. This study evaluates the long-term outcomes of HCV treatment with ledipasvir/sofosbuvir, focusing on mortality, viral relapse, and hepatocellular carcinoma (HCC) development. (2)

Methods

This prospective, longitudinal cohort study initially enrolled patients with chronic HCV in Mongolia between 2016 and 2017, focusing on those who completed the five-year follow-up (n = 303). The study measured long-term mortality, HCC development, and viral relapse, employing non-invasive methods to assess liver fibrosis and liver function. (3)

Results

At the outset, 98.2% of the patients achieved undetectable HCV RNA levels. Over five years, 6.27% experienced viral relapse and 3.30% developed hepatocellular carcinoma (HCC), with a mortality rate of 5.94%. In a multivariable analysis, the significant predictors for HCC occurrence included age (OR = 1.081, 95% CI = 1.021–1.145), liver cirrhosis (OR = 5.866, 95% CI = 1.672–22.577), and GGT level (OR = 1.011, 95% CI = 1.004–1.018). The independent predictors of mortality included age (OR = 1.083, 95% CI = 1.024–1.147), liver cirrhosis (OR = 6.529, 95% CI = 1.913–22.281), and GGT (OR = 1.011, 95% CI = 1.004–1.017). (4)

Conclusions

This study demonstrates that ledipasvir/sofosbuvir effectively suppresses HCV initially and maintains low viral relapse rates over the long term. However, it emphasizes the need for continued management to reduce the long-term risk of HCC and mortality, especially in patients with severe liver fibrosis or cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBenzimidazolesSofosbuvirFluorenesAntiviral AgentsHepatitis C, ChronicHumansMaleFemaleMiddle AgedProspective StudiesAgedLongitudinal StudiesHepacivirusTreatment OutcomeAdultLiver Cirrhosis

Stichwörter der Autor:innen

antiviral therapychronic liver diseaseliver cirrhosisviral suppression

Substanzen

BenzimidazolesSofosbuvirFluorenesAntiviral Agentsledipasvir, sofosbuvir drug combination

Autor:innen und Institutionen

  • Department of Health Research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
  • General Hospital of the Arkhangai Province, Tsetserleg 65191, Mongolia.
  • Health Department of the Arkhangai Province, Tsetserleg 65089, Mongolia.
  • Department of Physiology, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
  • Department of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
  • Mongolian Academy of Medical Sciences, Ulaanbaatar 14210, Mongolia.

ORCID-Profile: Oidov Baatarkhuu

Förderung

  • The Liver Disease Free Arkhangai project

Zitieren

APA

Byambasuren, A., Gyarvuulkhasuren, B., Erdenebat, B., Nyamdavaa, K., & Baatarkhuu, O. (2025). Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia. Viruses. https://doi.org/10.3390/v17060743

Vancouver

Byambasuren A, Gyarvuulkhasuren B, Erdenebat B, Nyamdavaa K, Baatarkhuu O. Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia. Viruses. 2025. doi:10.3390/v17060743

BibTeX
@article{Byambasuren2025,
  author = {Byambasuren, Amgalan and Gyarvuulkhasuren, Buyankhishig and Erdenebat, Byambatsogt and Nyamdavaa, Khurelbaatar and Baatarkhuu, Oidov},
  title = {Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17060743}
}
Kostenlos starten →